Connection

Meng Yuan to Antibodies, Viral

This is a "connection" page, showing publications Meng Yuan has written about Antibodies, Viral.
Connection Strength

0.498
  1. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021 08 13; 373(6556):818-823.
    View in: PubMed
    Score: 0.090
  2. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021 01 29; 538:192-203.
    View in: PubMed
    Score: 0.086
  3. Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020 08 28; 369(6507):1119-1123.
    View in: PubMed
    Score: 0.085
  4. NMR Based SARS-CoV-2 Antibody Screening. J Am Chem Soc. 2021 06 02; 143(21):7930-7934.
    View in: PubMed
    Score: 0.022
  5. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021 05 12; 29(5):806-818.e6.
    View in: PubMed
    Score: 0.022
  6. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021 02 12; 371(6530).
    View in: PubMed
    Score: 0.022
  7. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 2020 12; 16(12):e1009089.
    View in: PubMed
    Score: 0.022
  8. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020 12 15; 53(6):1272-1280.e5.
    View in: PubMed
    Score: 0.022
  9. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Rep. 2020 10 20; 33(3):108274.
    View in: PubMed
    Score: 0.021
  10. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell. 2020 11 12; 183(4):1058-1069.e19.
    View in: PubMed
    Score: 0.021
  11. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020 08 21; 369(6506):956-963.
    View in: PubMed
    Score: 0.021
  12. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020 06 02; 31(9):107725.
    View in: PubMed
    Score: 0.021
  13. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020 05 08; 368(6491):630-633.
    View in: PubMed
    Score: 0.021
  14. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice. Eur J Immunol. 2021 09; 51(9):2296-2305.
    View in: PubMed
    Score: 0.006
  15. Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. Cell Rep. 2021 05 25; 35(8):109173.
    View in: PubMed
    Score: 0.006
  16. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Rep. 2021 05 11; 35(6):109109.
    View in: PubMed
    Score: 0.006
  17. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020 06 02; 31(9):107725.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.